Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKUCVE:LXGNASDAQ:ONCCVE:SQD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKUAkumin$0.18$0.12▼$1.90$26.32M-0.721.38 million shs8.54 million shsLXGLexaGeneC$0.11-19.2%C$0.11C$0.07▼C$0.31C$14.77M2.26170,061 shs2.14 million shsONCBeOne Medicines$245.49+0.5%$247.69$142.00▼$287.88$26.78B0.28359,147 shs172,489 shsSQDSQI DiagnosticsC$0.02C$0.02C$0.01▼C$0.18C$6.11M-0.21172,133 shs65,000 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKUAkumin0.00%0.00%0.00%0.00%0.00%LXGLexaGene0.00%0.00%0.00%0.00%0.00%ONCBeOne Medicines+0.48%-3.54%-2.47%+2.93%+24,548,999,900.00%SQDSQI Diagnostics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKUAkuminN/AN/AN/AN/AN/AN/AN/AN/ALXGLexaGeneN/AN/AN/AN/AN/AN/AN/AN/AONCBeOne Medicines3.5669 of 5 stars4.50.00.00.03.11.70.6SQDSQI DiagnosticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKUAkumin 0.00N/AN/AN/ALXGLexaGene 0.00N/AN/AN/AONCBeOne Medicines 3.00Buy$320.6730.62% UpsideSQDSQI Diagnostics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest AKU, ONC, YGEN, LXG, and SQD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025ONCBeOne MedicinesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$313.00 ➝ $330.006/27/2025ONCBeOne MedicinesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$317.00 ➝ $321.006/27/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$311.005/8/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$312.00 ➝ $311.005/8/2025ONCBeOne MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$348.00 ➝ $350.004/28/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$312.00 ➝ $312.004/24/2025ONCBeOne MedicinesTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$334.00 ➝ $334.004/21/2025ONCBeOne MedicinesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$311.00 ➝ $317.004/16/2025ONCBeOne MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/10/2025ONCBeOne MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$348.00 ➝ $348.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKUAkumin$749.63M0.00N/AN/A$1.24 per share0.00LXGLexaGeneC$110.93K133.13C$0.00 per share21.25C$0.01 per share10.50ONCBeOne Medicines$4.18B6.44N/AN/A$34.10 per share7.20SQDSQI DiagnosticsC$3.04M2.01C$0.00 per share8.50C($0.04) per share-0.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKUAkumin-$156.76M-$2.52N/AN/AN/A-30.56%-167.86%-7.81%N/ALXGLexaGene-C$8.54M-C$0.08N/A∞N/AN/A-339.54%-120.21%N/AONCBeOne Medicines-$644.79M-$3.72N/A345.76N/A-9.40%-7.55%-4.42%N/ASQDSQI Diagnostics-C$19.14M-C$0.05N/A∞N/AN/AN/A-74.70%N/ALatest AKU, ONC, YGEN, LXG, and SQD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025ONCBeOne Medicines-$0.71$1.22+$1.93$0.01$1.12 billion$1.12 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKUAkuminN/AN/AN/AN/AN/ALXGLexaGeneN/AN/AN/AN/AN/AONCBeOne MedicinesN/AN/AN/AN/AN/ASQDSQI DiagnosticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKUAkumin17.020.990.99LXGLexaGene138.011.391.13ONCBeOne Medicines0.051.961.71SQDSQI Diagnostics464.330.120.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKUAkumin36.10%LXGLexaGene0.09%ONCBeOne Medicines48.55%SQDSQI Diagnostics25.15%Insider OwnershipCompanyInsider OwnershipAKUAkumin20.51%LXGLexaGene17.85%ONCBeOne Medicines6.62%SQDSQI Diagnostics50.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKUAkumin3,63191.17 million72.47 millionNot OptionableLXGLexaGene41140.64 millionN/ANot OptionableONCBeOne Medicines11,000109.60 million102.34 millionN/ASQDSQI Diagnostics147,000407.17 millionN/ANot OptionableAKU, ONC, YGEN, LXG, and SQD HeadlinesRecent News About These CompaniesArchival Footage of D-DayNovember 1, 2024 | smithsonianmag.comSHow bioinformatics is revolutionizing genetic diagnostics?August 3, 2024 | dqindia.comDBVAXF BioVaxys Technology Corp.March 28, 2024 | seekingalpha.comSQI Diagnostics Announces Receipt of Intention to Enforce Security from Pivot Financial and Anticipated Voluntary Bankruptcy FilingJune 16, 2023 | finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - SQDJune 6, 2023 | finance.yahoo.comThis SQI Diagnostics Insider Increased Their Holding In The Last YearMay 18, 2023 | finance.yahoo.comClosing Bell: Sqi Diagnostics Inc flat on Friday (SQD)May 17, 2023 | theglobeandmail.comClosing Bell: Sqi Diagnostics Inc up on Friday (SQD)April 29, 2023 | theglobeandmail.comClosing Bell: Sqi Diagnostics Inc up on Wednesday (SQD)April 26, 2023 | theglobeandmail.comClosing Bell: Sqi Diagnostics Inc down on Monday (SQD)April 25, 2023 | theglobeandmail.comClosing Bell: Sqi Diagnostics Inc down on Thursday (SQD)April 21, 2023 | theglobeandmail.comClosing Bell: Sqi Diagnostics Inc down on Friday (SQD)April 15, 2023 | theglobeandmail.comClosing Bell: Sqi Diagnostics Inc flat on Wednesday (SQD)April 12, 2023 | theglobeandmail.comClosing Bell: Sqi Diagnostics Inc flat on Tuesday (SQD)April 11, 2023 | theglobeandmail.comSQI DIAGNOSTICS ANNOUNCES ISSUANCE OF PREVIOUSLY ANNOUNCED BONUS WARRANTSMarch 20, 2023 | finance.yahoo.comSQI DIAGNOSTICS EXTENDS MATURITY DATE OF PIVOT CREDIT FACILITY AND DEFERRAL OF CERTAIN INTEREST PAYMENTSFebruary 6, 2023 | ca.finance.yahoo.comThe Independent Director of SQI Diagnostics Inc. (CVE:SQD), Gerald Connor, Just Bought 5.8% More SharesDecember 9, 2022 | finance.yahoo.comSQI DIAGNOSTICS EXTENDS MATURITY DATE OF PIVOT CREDIT FACILITY AND ANNOUNCES DEFERRAL OF CERTAIN INTEREST PAYMENTSOctober 19, 2022 | finance.yahoo.comSQI Diagnostics: Top 10 Undervalued Medical Diagnostics & Research Industry Sector Stocks on TSX Venture Exchange (SQD)September 18, 2022 | theglobeandmail.comSQI Diagnostics reports Q3 resultsAugust 30, 2022 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeRKLB Breakout Fails Near Highs: Should Investors Be Concerned?By Ryan Hasson | June 11, 2025View RKLB Breakout Fails Near Highs: Should Investors Be Concerned?Want AI Exposure? These 3 ETFs Offer Different AnglesBy Chris Markoch | June 9, 2025View Want AI Exposure? These 3 ETFs Offer Different AnglesIGM ETF: Expand Tech Exposure With Top AI LeadersBy Jeffrey Neal Johnson | July 1, 2025View IGM ETF: Expand Tech Exposure With Top AI LeadersAKU, ONC, YGEN, LXG, and SQD Company DescriptionsAkumin NASDAQ:AKUAkumin Inc. provides outpatient diagnostic imaging services in the United States. It operates in two segments, Radiology and Oncology. The company offers various medical imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other diagnostic and interventional radiology procedures through owned and/or operated imaging locations. It provides outpatient radiology, and oncology services and solutions to hospitals and health systems across 48 states. Akumin Inc. was founded in 2015 and is headquartered in Plantation, Florida.LexaGene CVE:LXGC$0.10 -0.03 (-19.23%) As of 02/21/2023LexaGene Holdings Inc., a biotechnology company, engages in the research, development, and commercialization of pathogen detection systems. It offers MiQLab, an automated pathogen detection system that aims to transform pathogen detection in veterinary diagnostics, human clinical diagnostics, food and water safety testing, and other life sciences markets. Its automated pathogen detection platform is used at the site of sample collection, which offers unprecedented ease-of-use, sensitivity, and breadth of pathogen detection. The company was incorporated in 2007 and is headquartered in Beverly, Massachusetts.BeOne Medicines NASDAQ:ONC$245.49 +1.17 (+0.48%) As of 07/3/2025 01:00 PM EasternBeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.SQI Diagnostics CVE:SQDC$0.02 0.00 (0.00%) As of 06/14/2023SQI Diagnostics Inc., a precision medicine company, discovers, develops, and commercializes rapid diagnostic testing services for healthcare providers, patients, and consumers worldwide. The company also offers TOR-dx, a lung test, which enables the surgeon to assess the health of the donor's lung; and a COVID-19 at-home antibody test kit; the RALI-Dx, a COVID-19 severity triage lab test; and RALI-fast, a COVID-19 severity triage POC test. In addition, it offers microarray tests for protein and antibody testing workflow. The company was founded in 1999 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
